Abstract

Introduction
Prostate cancer is the most common cancer in UK males, with nearly 40,000 men diagnosed in 2014, and the second commonest cause of male cancer-related mortality. The clinical conundrum is that most men live with prostate cancer rather than die from it, while existing treatments have significant associated morbidity. Recent studies have shown very low mortality rates (1% after a median 10-years follow-up), and no treatment related reductions in mortality, in men with localised prostate cancer. This study will identify prognostic factors associated with prostate cancer progression to help differentiate aggressive from more indolent tumours in men with localised disease at diagnosis, and so inform the decision to adopt conservative (active surveillance) or radical (surgery or radiotherapy) management strategies.
Methods & analysis
The Clinical Practice Research Datalink (CPRD) contains 57,318 men who were diagnosed with prostate cancer between 01/01/1987 and 31/12/2016. These men will be linked to the Office for National Statistics (ONS) and the National Cancer Registration and Analysis Service (NCRAS) registry databases for mortality, TNM stage, Gleason grade, and treatment data.
Men with a diagnosis date prior to 01/01/1987 and men with lymph node or distant metastases at diagnosis will be excluded. A priori determined prognostic factors potentially associated with prostate cancer mortality, the end point of cancer progression, will be measured at baseline, and the participants followed through to development of cancer progression, death, or the end of the follow-up period (31/12/2016). Cox proportional hazards regression will be used to estimate crude and mutually adjusted hazard ratios.
Mortality risk will be predicted using flexible parametric survival models that can accurately fit the shape of the hazard function.
Ethics & dissemination
This study protocol has approval from the Independent Scientific Advisory Committee (ISAC) Each of the hypothesised prognostic factors for prostate cancer mortality identified a priori (see Table 1 ) will be recorded as an 'exposure' if it is entered into the patient record at the study baseline (index date), or recorded before the diagnosis of prostate cancer is entered.
Continuous variables, such as height, weight and the biochemical markers, will be measured according to the most recent result prior to the coding of a diagnosis of prostate cancer within the study time period. Genetic factors, lifestyle exposures, medications and comorbidities will be considered in a binary manner in relation to their presence or absence at the index date. Missing data will be controlled for using multiple imputation methods. To achieve 95% power and detect a difference in hazard ratios of 0.5 in prostate cancer mortality for a binary risk factor using an alpha of 0.05, a sample of at least 8,762 men with prostate cancer would be required, assuming a 1% annual mortality rate over a median 10-year follow-up.
Category Prognostic factor(s)
The primary outcome measure will be prostate cancer mortality, provided by linked cancer registry data. Secondary outcome measures of prostate cancer progression will include allcause mortality, change from localised to metastatic disease, and commencing antiandrogen therapy or chemotherapy. We will use whether the treatment recorded in the registry is stated to be localised (i.e. 1 tumour treated) or systemic (i.e. >1 tumour treated)
to help distinguish between early and advanced disease.
Descriptive statistics will be used to summarise the basic demographic details of the men.
The prevalence of the pre-selected putative prognostic factors will be calculated and presented. Cox proportional hazards regression will be used to estimate the crude and This analysis will be repeated with stratification by stage at diagnosis. In order to allow for flexibility in the shape of the cumulative hazard function we will use flexible parametric survival models for prognostic modelling. These models incorporate cubic spline terms in the log cumulative hazard function and are based on weibull, loglogistic or lognormal distributions of survival time. We will check for non-linearities in the effects of continuous predictors using fractional polynomials and also test for time varying effects of prognostic factors. We will determine mortality risk in groups defined by important prognostic factors. To asses competing risks, we will use cause-specific survival analysis to estimate at 1, 2, 5 and 10 years post prostate cancer diagnosis the contribution of prostate cancer mortality to overall mortality in those who have died by prognostic factor combinations . 
Ethics and dissemination
This study protocol has approval from the Independent Scientific Advisory Committee (ISAC)
for the UK Medicines and Healthcare products Regulatory Agency (MHRA) Database
Research (protocol 17_041).
The findings of this study will be submitted as a manuscript to peer reviewed journal to aid dissemination to clinicians and other researchers in the field. It will also be presented and discussed at local CPRD working groups to inform other researchers' methods using the CPRD database. Subsequent studies of the prediction tool, based on this piece of research, will involve clinicians at every stage to ensure the final tool is acceptable for use in clinical practice. 
Conclusions
This study will lay the foundation for the development of a clinically useful risk prediction tool. Clinicians will be able to use the tool, inputting routine primary care data, to improve shared decision making about an individual's prognosis and, if validated and shown effective in trials, inform their practice when deciding with patients whether to undergo radical surgery or radiotherapy or be followed up conservatively using active monitoring.
Patients will also benefit from this work in other ways. They will be able to receive more information from GPs and NHS specialists about the risk of progression of their prostate cancer, and they will be able to decide within a shared decision-making framework with their doctors about the potential benefits and harms of undergoing radical treatment or active monitoring. 
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08( $9 ( 0 ; D 2 -*9 $(! .! 7.( +% 5 " E( # ,5 " 5 , " , DR / 9 $ 5 " * % 5 9 5 C ! % T 2 "& ; + & # ' % * * 7 $? ;! I +! . 7 . . Men with a diagnosis date prior to 01/01/1987 and men with lymph node or distant metastases at diagnosis will be excluded. A priori determined prognostic factors potentially associated with prostate cancer mortality, the end point of cancer progression, will be measured at baseline, and the participants followed through to development of cancer progression, death, or the end of the follow-up period (31/12/2016). Cox proportional hazards regression will be used to estimate crude and mutually adjusted hazard ratios.
Ethics & dissemination
for the UK Medicines and Healthcare products Regulatory Agency (MHRA) Database The Bristol-based ProtecT multi-centre trial randomised men with clinically localised prostate cancer to either active monitoring, radical surgery (prostatectomy) or radical radiotherapy. After a median of 10 years' follow-up there was no difference in prostate cancer mortality. Overall, the 10-year mortality rates were very low (1%), and men randomised to active monitoring were at an increased risk of clinical progression and development of metastatic disease (22.9 per 1,000 person years follow-up) compared to the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 This study aims to establish which risk factors are associated with prostate cancer progression using primary care medical records data. These findings, in combination with These men will form the basis of the study cohort. Additional mortality, staging (TNM and gleason grade), and treatment data will be obtained by using each man's NHS number to link them to the ONS (available from 01/01/1998) and National Cancer Registration and Analysis Service (NCRAS) (available from 01/01/1990) databases. The index date will be the date the diagnosis of prostate cancer was first entered into the primary care medical record.
From this date, the men will be followed until the date of their death, the development of prostate cancer progression, or the end of the cohort period, whichever is later. Men with a diagnosis date prior to 01/01/1987, and men with lymph node or distant metastases at diagnosis, will be excluded from the analysis.
Each of the hypothesised prognostic factors for prostate cancer mortality identified a priori (see Table 1 ) will be recorded as an 'exposure' if it is entered into the patient record at the study baseline (index date), or recorded before the diagnosis of prostate cancer is entered.
Category Prognostic factor(s) Definition/unit
The primary outcome measure will be prostate cancer mortality. Participants will be presumed to be alive at the end of the follow-up period if they have not been reported as deceased according to the ONS mortality data. Secondary outcome measures of prostate cancer progression will include all-cause mortality, change from localised to metastatic disease, and commencing anti-androgen therapy or chemotherapy. We will use whether the treatment recorded in the registry is stated to be localised (i.e. 1 tumour treated) or systemic (i.e. >1 tumour treated) to help distinguish between early and advanced disease.
The prevalence of the pre-selected putative prognostic factors will be calculated and presented. Cox proportional hazards regression will be used to estimate the crude and mutually adjusted hazard ratios (with 95% confidence intervals) for prostate cancer and allcause mortality according to the prognostic factors. Related prognostic factors, such as smoking and COPD, will also be grouped to account for potential intermediate variables.
This analysis will be repeated with stratification by stage at diagnosis. In order to allow for flexibility in the shape of the cumulative hazard function we will use flexible parametric survival models for prognostic modelling. These models incorporate cubic spline terms in the log cumulative hazard function and are based on weibull, loglogistic or lognormal distributions of survival time. We will check for non-linearities in the effects of continuous predictors using fractional polynomials and also test for time varying effects of prognostic factors. We will determine mortality risk in groups defined by important prognostic factors. To asses competing risks, we will use cause-specific survival analysis to estimate at 1, 2, 5 and 10 years post prostate cancer diagnosis the contribution of prostate cancer mortality to overall mortality in those who have died by prognostic factor combinations . The findings of this study will be submitted as a manuscript to peer reviewed journal to aid dissemination to clinicians and other researchers in the field. It will also be presented and discussed at local CPRD working groups to inform other researchers' methods using the CPRD database. Subsequent studies of the prediction tool, based on this piece of research, will involve clinicians at every stage to ensure the final tool is acceptable for use in clinical practice. 
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